Oppenheimer Launches Coverage on DTIL with Outperform Rating – 100%+ Upside Ahead?
Oppenheimer rates DTIL “Outperform” ($20). ARCUS gene editing shows promise in DMD & Hep B with big upside potential.
Already have an account? Sign in.